Avid Bioservices Inc (CDMO)

[biopharm]

David Carbone : Peregrine Pharmaceuticals KOL and IASLC President:

Now if there is huge potential in a subset of patients in sclc that makes up about 15% of all lung cancer, then the subset in nsclc which makes up about the other 85% must be astronomical : )

It is all about just getting close to approval in any indications and any subset....

Expert Examines Immunotherapy Potential in Small Cell Lung Cancer
Gina Columbus @ginacolumbusonc

Published Online: Thursday, May 12, 2016

Several ongoing clinical trials are examining the efficacy and safety of immunotherapy agents in patients with small cell lung cancer (SCLC), explains David P. Carbone, MD, PhD.
..
..
..
OncLive: Is there potential for immunotherapy in lung cancer subtypes other than non–small cell lung cancer?
Carbone: Absolutely. There is a huge potential for it in a small subset of patients. Therefore, we have to figure out who that subset is. There are early hints that immunotherapy is active in small cell lung cancer and mesothelioma. Both of those diseases are areas of great need.
..
..

http://www.onclive.com/web-exclusives/expert-examines-immunotherapy-potential-in-small-cell-lung-cancer